Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on ...

MENOPAUSAL THERAPY IN FOCUS — The FDA will hold a panel discussion Thursday on hormone therapy for menopausal women, a pet ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

On Thursday in Washington, D.C., the U.S. Food and Drug Administration (FDA) convened a panel of top experts to reassess the ...

Doctors now recognize the need to approach testosterone deficiency with the same clinical rigour as other hormone ...

“The role of testosterone is just a lesson in gender bias,” says Kelly Casperson, MD, a urologist. “Because 100 percent of ...

Puerto Rican Gov. Jennifer Gonzalez signed a bill into law that bans hormone therapy and gender-affirming surgeries for ...

The Food and Drug Administration is reassessing some warnings given about hormone therapy treatments for menopause that have ...

A transgender woman incarcerated in Eastern Kentucky is suing the state's prison system over a plan to cut off her ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

An Food and Drug Administration expert panel on Thursday endorsed removing the "black box" warning on hormone treatments for ...